Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Wednesday 20 February, 2019

EKF Diagnostics Hldg

US FDA approval for Quo-Test analyser

RNS Number : 5328Q
EKF Diagnostics Holdings PLC
20 February 2019


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).


EKF Diagnostics Holdings plc

("EKF", the "Company")


US FDA approval for Quo-Test analyser


EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.


The Quo-Test is a fully automated glycated haemoglobin (HbA1c) analyser, providing fast, easy and reliable HbA1c measurement for the monitoring and management of diabetes.


The FDA 510(k) clearance allows the Quo-Test to be used in a laboratory setting for in-vitro quantitative determination of HbA1c in whole blood samples. 


For more information on the Quo-Test see:


Commenting, Julian Baines, CEO of EKF, said:

"We are very pleased with the FDA approval of Quo-Test as this increases the portfolio of products that can now be marketed in the US."



EKF Diagnostics Holdings plc

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

Walbrook PR Limited                                                                           Tel: 020 7933 8780 or [email protected] 

Paul McManus/ Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303


About EKF Diagnostics Holdings plc (

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t